Ascelia Pharma AB (publ) (ACE.ST)
- Previous Close
3.7300 - Open
3.7300 - Bid 3.6550 x --
- Ask 3.6700 x --
- Day's Range
3.5850 - 3.7650 - 52 Week Range
1.8886 - 11.6800 - Volume
949,880 - Avg. Volume
780,530 - Market Cap (intraday)
351.267M - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4800 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.71
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.
www.ascelia.comRecent News: ACE.ST
View MorePerformance Overview: ACE.ST
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACE.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACE.ST
View MoreValuation Measures
Market Cap
358.48M
Enterprise Value
308.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.35%
Return on Equity (ttm)
-104.43%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-80.03M
Diluted EPS (ttm)
-1.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
75.26M
Total Debt/Equity (mrq)
32.17%
Levered Free Cash Flow (ttm)
-16.1M